產品(pǐn)編號：Y0702

英(yīng)文名(míng)稱：Chenodeoxycholic acid

CAS號(hào) 474-25-9

分(fēn)析標準品

分子式(shì) C24H40O4 分子(zǐ)量392.58

基本信(xìn)息(xī):

敏感性對光(guāng)敏(mǐn)感

密度(dù)1.128

存貯條件密封(fēng)避光保(bǎo)存。

描(miáo)述(shù)

產品介(jiè)紹味苦，有(yǒu)異(yì)臭(chòu)。易(yì)溶於乙醇(chún)，甲醇(chún)，丙(bǐng)酮和乙酸，幾乎(hū)不溶於水，石油醚(mí)和苯(běn)。

別名鵝(é)去(qù)氧(yǎng)膽酸(suān) ;脫氧鵝膽酸(suān)；鵝脫氧膽酸；3α,7α-二(èr)羥(qiǎng)基膽(dǎn)質酸；3α,7α-二羥基(jī)-5-β-膽烷酸;

生化機(jī)理(lǐ)

Chenodeoxycholic Acid (CDCA), is a hydrophobic primary bile acid that activates nuclear receptors involved in cholesterol metabolism. Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulates genes involved in lipid metabolism. EC50 concentrations for activation of FXR range from 13-34 μM. In cells, Chenodeoxycholic Acid also binds to bile acid binding proteins (BABP) with a reported stiochiometery of 1:2. Chenodeoxycholic Acid toxicity is linked to increased cellular glutathione levels and increased oxidative stress. Exposure of cells to excess Chenodeoxycholic Acid contributes to liver and intestinal cancers.

應用主(zhǔ)要(yào)用於(yú)合(hé)成熊去(qù)氧膽酸。

膽石(shí)溶(róng)解(jiě)劑(jì)，用(yòng)於(yú)膽固醇高而(ér)引起的結(jié)石(shí)，膽道炎(yán)和膽囊(náng)炎等。